PASSIFLORA INCARNATA FORTE 2700 MG
Food supplement declared in France, declaration No 2018-6-493, decision dated 14 June 2018
PASSIFLORA INCARNATA FORTE 2700 MG (RELAFIT) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Passiflora incarnata 250 mg per day, Passiflora incarnata 200 mg per day. None of the rules we check flags an issue with its declared composition.
- Brand
- RELAFIT
- Food business operator placing the product on the market
- LABORATORIOS MORALES SOLER, S.L.
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 CAPSULE PAR JOUR
- Directions for use
- PRENDRE 1 CAPSULE PAR JOUR DANS LE DINNER
Declaration 262366, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Passiflora incarnata L. | Sommités fleuries | Extrait sec aqueux | 250 mg |
| Passiflora incarnata L. | Sommités fleuries | Poudre (de plantes séchées ou broyées) | 200 mg |
Additives
E470b
Other ingredients
gélatine
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
VOIR ETIQUETAGE POUR VOIR LES AVERTISSEMENTS
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Passiflora incarnata L.
Read the warning, when it applies and the studies cited
PASSIONFLOWER -PASSIFLORA INCARNATA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : RELAFIT
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “PASSIFLORA INCARNATA FORTE 2700 MG (RELAFIT): composition and regulation”, https://compoatlas.com/en/supplements/products/262366-passiflora-incarnata-forte-2700-mg, updated 15 November 2026.